---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-003281"
form_type: "8-K"
ticker: "ODYY"
cik: "0001626644"
company_name: "Odyssey Health, Inc."
filed_at: "2022-05-06T23:59:59+00:00"
generated_at: "2026-06-25T23:01:35.594009+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Odyssey Health reports positive initial Phase I results for concussion drug PRV-002

## Summary
- First group of 5 healthy subjects dosed with PRV-002 showed safety and tolerability; no serious adverse events.
- Phase I trial ongoing with 48 healthy subjects in single and multi-ascending dose components.
- Company plans to present Phase I data to FDA, then initiate Phase II trial in US starting with military.
- Concussion affects over 3 million annually in US; no FDA-approved treatment currently exists.

## SEC filing metadata
- accession: 0001683168-22-003281
- form_type: 8-K
- ticker: ODYY
- cik: 0001626644
- company_name: Odyssey Health, Inc.
- filed_at: 2022-05-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626644/000168316822003281/0001683168-22-003281-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626644/000168316822003281/ody_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-003281
- JSON: https://secwatch.observer/filing/0001683168-22-003281.json
- Plain text: https://secwatch.observer/filing/0001683168-22-003281.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.